Effect of a single hemodialysis session on endothelial dysfunction

Journal of Nephrology

Volumn 24, Issue 1, 2011, Pages 83-90

  Errakonda, Prabhakar Reddy ^a   Paladugu, Ramakrishna ^a   Bitla, Aparna R ^a   Musturu, Suchitra M ^a   Lakshman, Jayaseelan ^b   Pemmaraju, Srinivasa Rao V L N ^a   Vishnubhotla, Sivakumar ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Asymmetric dimethylarginine; Endothelial dysfunction; Hemodialysis; Homocysteine; Lipoprotein associated phospholipase A2; Nitrate

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARGININE; BIOCHEMICAL MARKER; CITRULLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HOMOCYSTEINE; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; TETRAHYDROBIOPTERIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; LIPID PEROXIDATION; OUTCOME ASSESSMENT; OXIDATION KINETICS; OXIDATIVE STRESS; PATIENT CARE; PROTEIN ANALYSIS; THERAPY EFFECT; TREATMENT DURATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARGININE; BIOLOGICAL MARKERS; CITRULLINE; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HUMANS; INDIA; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALONDIALDEHYDE; MIDDLE AGED; NITRATES; NITRIC OXIDE; OXIDATIVE STRESS; RENAL DIALYSIS; TIME FACTORS;

EID: 78651255043     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.4926     Document Type: Article

References (50)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050-1065.
2. Zoccali C. Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000;15:454-457.
3. Bian K, Murad F. Nitric oxide (NO): biogeneration, regulation, and relevance to human disease. Front Biosci. 2003;8:264-278.
4. Miyazaki H, Matsuoka H, Itabe H, et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin Ecoated dialyzer. Circulation. 2000;101:1002-1006.
5. Cross JM, Donald A, Vallance PJ, Deanfield JE, Woolfson RG, MacAllister RJ. Dialysis improves endothelial function in humans. Nephrol Dial Transplant. 2001;16:1823-1829. (Pubitemid 32821414)
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
7. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594-600.
8. Boger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl. 2003;4:23-28.
9. Buccianti G, Baragetti I, Bamonti F, Furiani F, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol. 2004;17:405-410.
10. Austen SK, Coombes JS, Fassett RG. Homocysteine and cardiovascular disease in renal disease. Nephrology. 2003;8:285-295.
11. Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. J Hypertens. 2000;18:1207-1213.
12. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol. 2004;38:405-416.
13. Cottone S, Lorito MC, Riccobene R, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008;21:175-179.
14. Goi G, Massaccesi L, Baquero Herrera CJ, et al. Oxidative stress in elderly chronic renal failure patients: effects of renal replacement therapies on cell membrane fluidity. J Nephrol. 2009;22:630-636.
15. Silva AM, Signori LU, Plentz RD, et al. Hemodialysis improves endothelial venous function in end-stage renal disease. Braz J Med Biol Res. 2008;41:482-488.
16. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann K-H, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant. 1996;11:2449-2452.
17. Nair AP, Nemirovsky D, Kim M, et al. Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med. 2005;72:365-373.
18. Clermonta G, Lecoura S, Laheta JJ, et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res. 2000;47:618-623.
19. Hewitson CL, Whiting MJ, Barbara JA, Mangoni AA. Acute effects of haemodialysis on biochemical modulators of endothelial function. J Intern Med. 2007;262:571-580.
20. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int. 1998;53:1068-1077.
21. Kocak H, Ceken K, Yavuz A, et al. Effect of renal transplantation on endothelial function in haemodialysis patients. Nephrol Dial Transplant. 2006;21:203-207.
22. x) reflect brachial flow-mediated dilation responses in young men and women. Clin Exp Pharmacol Physiol. 2007;34:1291-1293.
23. Rajendra W. High performance liquid chromatographic determination of amino acids in biological samples by precolumn derivation with O-phthaldialdehyde. J Liq Chromatogr. 1987;10:941-955. (Pubitemid 17107395)
24. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by kinetic cadmium reduction method. Clin Chem. 1990;36:1440-1443.
25. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med. 1990;8:15-19. (Pubitemid 120037505)
26. Catignani GL, Bieri JG. Simultaneous determination of retinol and a tocopherol in serum or plasma by liquid chromatography. Clin Chem. 1983;29:708-712. (Pubitemid 13109716)
27. Amore A, Bonaudo R, Ghigo D, et al. Enhanced production of nitric oxide by blood-dialysis membrane interaction. J Am Soc Nephrol. 1995;243:1278-1283.
28. Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uraemia: implication for platelet dysfunction and dialysis hypotension. Kidney Int. 1993;44:445-450.
29. Rysz J, Luciak M, Kedziora J, Blaszczyk J, Sibinska E. Nitric oxide release in the peripheral blood during hemodialysis. Kidney Int. 1997;51:294-300.
30. Yokokawa K, Mankus R, Saklayen MG, et al. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med. 1995;123:35-37.
31. Raj DS, Vincent B, Simpson K, et al. Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin. Kidney Int. 2002;61:697-704.
32. Lau T, Owen W, Yu YM, et al. Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest. 2000;105:1217-1225.
33. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575. (Pubitemid 33104795)
34. Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2000;36:758-765.
35. Woo KS, Chook P, Lolin YI, Sanderson JE, Metrewell C, Celermaler DS. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol. 1999;34:2002-2006.
36. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocystenemia in patients with chronic renal failure. Kidney Int. 1997;52:495-502.
37. Stuehr DJ, Marletta MA. Induction of nitrite/nitrate in murine macrophages by BCG infection, lymphokines or interferongamma. J Immunol. 1987;139:518-525.
38. Srinivasa Rao PV, Dakshinamurty KV, Saibaba KS, et al. Oxidative stress in haemodialysis: intradialytic changes. Redox Rep. 2001;6:303-309.
39. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000-1006.
40. Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int. 2002;62:1408-1416.
41. Pertosa G, Grandaliano G, Gesualdo L, Schena FP. Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl. 2000;76:S104-S111.
42. Walter R, Mischak H, Haller H. Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients. Nephrol Dial Transplant. 2002;17(Suppl 3):24-29. (Pubitemid 34450114)
43. Gesualdo L, Pertosa G, Grandaliano G, Schena FP. Cytokines and bioincompatibility. Nephrol Dial Transplant. 1998;13:1622-1626.
44. Koulouridis E, Tzilianos M, Katsarou A, et al. Homocysteine and C-reactive protein levels in hemodialysis patients. Int Urol Nephrol. 2001;33:207-215.
45. Korevaar JC, Van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT; NECOSAD group. Effect of increase in C-reactive protein level during a haemodialysis session on mortality. J Am Soc Nephrol. 2004;15:2916-2922.
46. Matsubara K, Stenvinkel P, Qureshi AR, et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol. 2009;22:774-782.
47. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007; 115: 2715-2721.
48. Sudhir K. Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endo Met. 2005;90:3100-3105.
49. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis. 2001;38:1408-1413.
50. Stam F, van Guldener C, Schalkwijk CG, et al. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 2003;18:892-898.